Right ventricular functional recovery after acute myocardial infarction: relation with left ventricular function and interventricular septum motion. GISSI-3 echo substudy


Objective: To evaluate the pattern of right ventricular (RV) functional recovery and its relation with left ventricular (LV) function and interventricular septal (IVS) motion in low risk patients after acute myocardial infarction (AMI).

Design and setting: Multicentre clinical trial carried out in 47 Italian coronary care units.

Patients: 500 patients from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico) -3 echo substudy, who underwent serial echocardiograms 24–48 hours after symptom onset and at discharge, six weeks, and six months after AMI.

Results: Tricuspid annular plane systolic excursion (TAPSE) increased significantly during follow up (mean (SD) 1.79 (0.46) cm at 24–48 hours to 1.92 (0.46) cm at six months, p < 0.001) and the increase was already significant at discharge (1.88 (0.47) cm, p < 0.001). LV ejection fraction (LVEF) was the best correlate of TAPSE at 24–48 hours (r = 0.15, p = 0.001). TAPSE increased significantly in patients both with reduced (< 45%) and with preserved (≥ 45%) LVEF, but the magnitude of increase was higher in patients with lower initial LVEF (p = 0.001). Improvement in IVS wall motion score index (IVS-WMSI) was the only independent predictor of TAPSE changes during follow up (r = −0.12, p = 0.007).

Conclusions: In low risk patients after AMI, RV function recovered throughout six months of follow up and was already significant at discharge. TAPSE was significantly related to LVEF at 24–48 hours. The magnitude of RV functional recovery was higher in patients with lower initial LVEF. RV functional recovery is best related to IVS-WMSI improvement, suggesting that IVS motion has an important role in RV functional improvement in this setting.

METHODS

Patients

The GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico)-3 echo substudy initially evaluated 878 patients among the 19,394 patients randomly assigned to treatment within the GISSI-3 study. Patients were initially considered eligible if they had confirmed AMI as previously reported and echocardiogram recordings suitable for qualitative and quantitative analyses. The protocol required serial echocardiograms 24–48 hours (mean (SD) 36 (8) hours) after symptom onset and at hospital discharge (12 (5) days), six weeks (48 (9) days), and six months (194 (17) days) after AMI.4 The protocol was approved by the local ethics committee. Patients gave their informed consent.

Echocardiographic study

All the echocardiograms were submitted to the core laboratory at the research centre of the National Association of Hospital Cardiologists (Associazione Nazionale Medici Cardiologi Ospedalieri) in Florence for an assessment of quality and suitability for quantitative analysis. Scans were considered acceptable if they allowed visualisation of all myocardial segments from at least two complementary or orthogonal views and visual assessment of both endocardial motion and myocardial thickening. All parameters analysed were calculated as the mean of at least three measurements. For wall motion analysis a 16 segment model was used and each myocardial segment was scored according to the American Society of Echocardiography recommendations.5 Videotapes were analysed centrally by three expert investigators unaware of patients’ clinical, ECG, or angiographic data, who assigned the wall motion score to each segment by consensus. Our interobserver and intraobserver reproducibility is best related to IVS-WMSI improvement, suggesting that IVS motion has an important role in RV functional improvement in this setting.

Abbreviations: AMI, acute myocardial infarction; BSA, body surface area; GISSI, Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico; IVS, interventricular septum; LAA, left atrial maximum end systolic area; LV, left ventricular; LVEF, left ventricular ejection fraction; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion; WMSI, wall motion score index
Table 1. Baseline characteristics of the study population (n = 500)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>414 (82.8%)</td>
</tr>
<tr>
<td>Age &gt;70 years</td>
<td>110 (22.0%)</td>
</tr>
<tr>
<td>Site of infarction</td>
<td></td>
</tr>
<tr>
<td>Anterior</td>
<td>152 (30.4%)</td>
</tr>
<tr>
<td>Inferoposterior</td>
<td>156 (31.2%)</td>
</tr>
<tr>
<td>Multiple locations</td>
<td>15 (3.0%)</td>
</tr>
<tr>
<td>Non-Q wave</td>
<td>97 (19.4%)</td>
</tr>
<tr>
<td>Undefined</td>
<td>37 (7.4%)</td>
</tr>
<tr>
<td>Killip class at admission</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>431 (86.4%)</td>
</tr>
<tr>
<td>2</td>
<td>64 (12.8%)</td>
</tr>
<tr>
<td>3</td>
<td>4 (0.8%)</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>62 (12.5%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>173 (35.7%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>66 (13.5%)</td>
</tr>
<tr>
<td>Recommended treatments</td>
<td></td>
</tr>
<tr>
<td>Thrombolysis</td>
<td>351 (70.8%)</td>
</tr>
<tr>
<td>Intravenous β blockers</td>
<td>122 (25.7%)</td>
</tr>
<tr>
<td>Aspirin</td>
<td>432 (87.3%)</td>
</tr>
</tbody>
</table>

Follow up

The vital status at four years (dead or alive) was sought for all patients through the census office of their towns of residence by means of a prepaid return mail questionnaire. Information on death from any cause at the four year follow up was available for 469 (94%) of the 500 patients, who formed the final study population.

Statistical analysis

Descriptive data are given as mean (SD). Differences between patients were assessed by unpaired t testing and frequency of parameters by the χ² test. Differences of echocardiographic measurements between groups and changes over time within each group (time effect) as well as any interaction (different trends over time between groups) were assessed by repeated measures analysis of variance. Linear regression analysis was used and correlation coefficients were calculated by Pearson’s method. Stepwise multivariate linear regression analysis, with demographic, clinical, and echocardiographic variables included in the model, was performed to assess the independent predictors of TAPSE at 24–48 hours and of TAPSE changes. Variables included in the stepwise multivariate analysis were selected based on the best results of the univariate analyses (at the significance level of p < 0.10). Cardiac survival curves were computed with the Kaplan-Meier method. For this study the ability of TAPSE at 24–48 hours and of TAPSE changes to predict all cause mortality were assessed. Values of p < 0.05 were considered significant.

RESULTS

Clinical characteristics

Patients with reinfarction (23 of 878; 2.6%), myocardial revascularisation procedures (n = 75; 8.5%), or who died during the six month echocardiographic follow up (n = 36; 4.1%) and patients with incomplete echocardiographic follow up or images insufficient for quantitative analysis (n = 244; 27.8%) were excluded from analysis. The remaining 500 patients (414 men, mean age (SD) 60.8 (11.8) years, range 22–90 years) who survived six months after AMI and underwent all four echocardiographic examinations constituted the final study population. Table 1 presents baseline characteristics of the study group. These characteristics were comparable with those of the general population of the GISSI-3 trial discharged alive and followed up with echocardiographic examinations at six months.

Table 2 presents changes in echocardiographic parameters during follow up. The prevalence of significant mitral regurgitation (grade 2–3/3) did not change from 24–48 hours to six months: 7.1%, 10.4%, 8.8%, and 9.2%, respectively (p = 0.58). Clinical event occurrence during follow up was low (table 3). During the four year follow up period, 40 patients died, with an estimated overall survival of 91%.

RV function at 24–48 hours

Table 4 presents the correlations of TAPSE with the parameters at 24–48 hours. TAPSE was lower in patients with a previous myocardial infarction than in those with a first AMI (mean (SD) 1.67 (0.47) cm vs 1.81 (0.46) cm, p = 0.02). There were no significant differences in TAPSE at 24–48 hours with respect to sex, infarct location, use of thrombolysis, heart failure occurrence at six months, or vital status at four years. At stepwise multivariate regression analysis, LVEF was the only independent predictor of TAPSE at 24–48 hours (r = 0.15, p = 0.001).

RV functional change during follow up

There was a significant increase in TAPSE throughout follow up (fig 1), already present at discharge, reflecting early RV functional recovery (time effect F = 26.7, p < 0.001). Late RV functional recovery was also significant (time effect F = 7.3, p = 0.007).

Relation between RV and LV function at 24–48 hours and during follow up

At 24–48 hours, TAPSE was significantly lower in patients with LVEF < 45% (group A, n = 161) than in patients with LVEF ≥ 45% (group B, n = 339) (mean (SD) 1.68 (0.43) cm vs 1.85 (0.47) cm, p < 0.001). TAPSE increased significantly in both groups during follow up, but the magnitude of increase was higher in group A (between subjects effect F = 11.1, p = 0.001). TAPSE change was not different with respect to sex, infarct location, previous myocardial infarction, use of...
thrombolysis, heart failure occurrence at six months, or four year vital status. Table 5 presents the correlations of overall TAPSE changes (six months – 24–48 hours) with the parameters. At stepwise multivariate regression analysis IVS-WMSI changes emerged as the only independent predictor of TAPSE changes during follow up ($r = -0.12, p = 0.007$).

DISCUSSION

RV functional recovery

That RV function recovers soon and to a great extent after an ischaemic insult is a long standing concept, proved both experimentally and clinically. Global RV performance recovers within days, regardless of the patency status of the infarct related artery. Reperfusion facilitates recovery of RV function experimentally and clinically. Global RV performance ischaemic insult is a long standing concept, proved both experimentally and clinically. That RV function recovers soon and to a great extent after an

In this study TAPSE at 24–48 hours and TAPSE changes during follow up did not predict heart failure at six months or survival at four years. Exclusion of patients with adverse events during the six month echocardiographic follow up, the low mortality rate (no deaths at six months by design, four year mortality < 9%) in this selected low risk population with preserved LV ejection fraction, and our use of total mortality as the sole long term outcome event may account for this result. A more detailed analysis of survival determinants in this trial has been recently published.

RV functional recovery: the relation with LV function and IVS motion

Moller and colleagues showed that in AMI, RV function correlated significantly with LV function; they also found weak correlations of RV myocardial performance index with global LV WMSI. The present study showed that in this low risk population RV function was related to LV function at 24–48 hours. We also showed that during follow up RV function recovered in patients both with reduced and preserved LVEF, but the magnitude of change was higher in patients with lower initial LVEF.

The main finding of this study is the relation of follow up RV functional changes with global and regional LV functional changes and in particular with IVS-WMSI changes. Although at univariate analysis both LVEF changes and IVS-WMSI changes were significantly related to TAPSE changes, the only independent predictor of TAPSE changes at multivariate analysis was not global LVEF improvement but IVS-WMSI improvement. This suggests that the main mechanism of RV functional improvement in this setting is IVS motion itself.

This finding confirms the role of IVS motion in RV performance and is concordant with previous experimental studies showing that RV performance is dependent on LV septal contractile contributions transmitted through systolic ventricular interaction. In another study, the presence of

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Multi-variate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>R coefficient</td>
<td>p Value</td>
<td>R coefficient</td>
</tr>
<tr>
<td>Age</td>
<td>0.05</td>
<td>0.28</td>
</tr>
<tr>
<td>LVEF</td>
<td>0.03</td>
<td>0.49</td>
</tr>
<tr>
<td>IVS-WMSI</td>
<td>0.04</td>
<td>0.091</td>
</tr>
<tr>
<td>Global WMSI</td>
<td>0.02</td>
<td>0.61</td>
</tr>
<tr>
<td>LAAi</td>
<td>0.04</td>
<td>0.41</td>
</tr>
</tbody>
</table>

CK, creatine kinase; E, peak velocity of transmitral E wave; E/e', E wave deceleration time; MultiR, correlation coefficient for multiple regression; R, Pearson correlation coefficient.

Table 2. Changes in echocardiographic parameters after AMI during six month follow up (n = 500)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>24–48 hours (n=500)</th>
<th>At discharge (n=500)</th>
<th>6 weeks (n=500)</th>
<th>6 months (n=500)</th>
<th>Time effect p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDVi (ml/m²)</td>
<td>79.7 (19.2)</td>
<td>83.9 (22.6)</td>
<td>85.9 (24.9)</td>
<td>86.7 (26.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ESVi (ml/m²)</td>
<td>42.6 (15.2)</td>
<td>45.1 (18.3)</td>
<td>46.7 (20.5)</td>
<td>47.4 (22.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Global WMSI</td>
<td>1.60 (0.34)</td>
<td>1.57 (0.34)</td>
<td>1.55 (0.33)</td>
<td>1.52 (0.36)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IVS-WMSI</td>
<td>1.59 (0.53)</td>
<td>1.56 (0.53)</td>
<td>1.53 (0.51)</td>
<td>1.49 (0.51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LV-FWMSI</td>
<td>1.61 (0.34)</td>
<td>1.58 (0.34)</td>
<td>1.56 (0.35)</td>
<td>1.54 (0.36)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>47.2 (7.3)</td>
<td>47.2 (8.2)</td>
<td>46.9 (8.2)</td>
<td>46.9 (8.6)</td>
<td>0.25</td>
</tr>
<tr>
<td>TAPSE (cm)</td>
<td>1.79 (0.46)</td>
<td>1.88 (0.47)</td>
<td>1.89 (0.48)</td>
<td>1.92 (0.46)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LAAi (cm²/m²)</td>
<td>9.49 (2.00)</td>
<td>9.68 (2.14)</td>
<td>9.73 (2.01)</td>
<td>9.80 (2.03)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Data are mean (SD).

Table 3. Clinical events recorded during follow up in the study population (n = 500)

<table>
<thead>
<tr>
<th>Time of event</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>In-hospital events</td>
<td>AF or atrial flutter</td>
</tr>
<tr>
<td>Sustained VT</td>
<td>7 (1.4%)</td>
</tr>
<tr>
<td>2nd or 3rd degree AV block</td>
<td>23 (4.6%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Heart failure after discharge</td>
<td>At 6 weeks</td>
</tr>
<tr>
<td>At 6 months</td>
<td>116 (23.2%)</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; AV, atrioventricular; VT, ventricular tachycardia.

Table 4. Univariate and multivariate correlates of TAPSE at 24–48 hours after symptom onset (n = 500)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analysis</th>
<th>Multi-variate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>R coefficient</td>
<td>p Value</td>
<td>R coefficient</td>
</tr>
<tr>
<td>Age</td>
<td>0.05</td>
<td>0.28</td>
</tr>
<tr>
<td>LVEF</td>
<td>0.15</td>
<td>0.001</td>
</tr>
<tr>
<td>EDVi</td>
<td>0.03</td>
<td>0.49</td>
</tr>
<tr>
<td>ESVi</td>
<td>0.03</td>
<td>0.44</td>
</tr>
<tr>
<td>Global WMSI</td>
<td>0.03</td>
<td>0.49</td>
</tr>
<tr>
<td>IVS-WMSI</td>
<td>0.08</td>
<td>0.07</td>
</tr>
<tr>
<td>LV-FWMSI</td>
<td>0.01</td>
<td>0.78</td>
</tr>
<tr>
<td>E</td>
<td>0.08</td>
<td>0.091</td>
</tr>
<tr>
<td>E/e'</td>
<td>0.04</td>
<td>0.33</td>
</tr>
<tr>
<td>LAAi</td>
<td>0.02</td>
<td>0.61</td>
</tr>
<tr>
<td>Peak CK release</td>
<td>0.04</td>
<td>0.41</td>
</tr>
</tbody>
</table>

CK, creatine kinase; E, peak velocity of transmitral E wave; E/e’, E wave deceleration time; MultiR, correlation coefficient for multiple regression; R, Pearson correlation coefficient.
presence of IVS involvement was a significant determinant of RV response to exercise in patients with recent myocardial infarction, suggesting that IVS contraction may be important for the maintenance of RV function in patients after infarction with impaired LV function. Our study showed that even in patients at low risk after AMI, improvement in RV function is related to improvement in IVS wall motion abnormalities.

Although the IVS has long been regarded as a functional part of the LV, it has lately been shown that the IVS actually contributes to the systolic function of both ventricles. An experimental study showed that RV function was impaired as much with septal ligation as with right coronary artery ligation,20 showing that ischaemic injury to either the IVS or the RV free wall alters RV function and suggesting that both regions play a significant part in maintaining RV performance. The important role of the IVS in RV performance was later confirmed in patients by means of biventricular angiography, with thickening of the IVS being shown to contribute to the systolic contraction of both ventricles.21

To our knowledge, this study is the first showing the physiological insights into RV functional recovery after AMI.

Limitations
Echocardiography was first performed at 36 (8) hours from symptom onset, when it is possible that some RV function had already been recovered. Nevertheless, since our purpose was to assess not RV function at one moment in time but recovery of RV function serially, the possibility of partial RV functional recovery does not alter the conclusions of the study. RV systolic function was assessed only by measuring TAPSE. However, accurate methods such as radionuclide ventriculography and magnetic resonance imaging are time consuming, relatively expensive, and cannot be used at the bedside. The complex shape of the RV precludes an accurate volumetric assessment by echocardiography and poor endocardial definition usually limits calculation of RV fractional area change. TAPSE measurement is devoid of geometrical assumptions or traceable endocardial outlines, is easy to measure, reproducible, and feasible,22 has a very good correlation with RV ejection fraction,23 and is recognised as an important tool for assessing RV systolic function.22–24 Although the absolute changes of TAPSE were small, they were highly significant. The small magnitude of TAPSE changes can be explained by the small mean infarct size and lower severity of disease in this low risk population. The validity of our echocardiographic measurements in this study was ascertained by expert analysis in the core laboratory, with a low variability.3

Conclusions
This study shows that in low risk patients after AMI, RV function recovers throughout six month follow up and is already significant at discharge. TAPSE is significantly related to LVEF at 24–48 hours. RV function recovers in patients both with reduced and with preserved LVEF, but the magnitude of change is higher in patients with lower initial LVEF. RV function change is best related to IVS-WMSI improvement, suggesting that IVS motion has an important role in RV function improvement in this setting.

ACKNOWLEDGEMENTS
Drs B A Popescu and A C Popescu were supported by Research Fellowships of the Association for Research in Cardiology, Pordenone, Italy.

Authors’ affiliations
B A Popescu, F Antonini-Canterin, R Piazza, L Ascione, I Stoian, E Cervi, A C Popescu, G l Nicolosi, Ospedale Civile, A R C, Pordenone, Italy
P L Temporelli, P Giannuzzi, E Bosimini, The Fondazione Maugeri, Istituto di Ricerca e Cura a Carattere Scientifico, Veruno, Italy
F Gentile, Ospedale Bassini, Cinisello Balsamo, Italy
A P Maggioni, Centro Studi Associazione Nazionale Medici Cardiologi Ospedalieri, Florence, Italy
L Tavazzi, Ospedale S Matteo, Pavia, Italy

GISSI is sponsored by the Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy.

For list of investigators see reference 7 (appendix).

REFERENCES
A 35 year old man underwent elective angioplasty for a severe stenosis at the ostium of the left anterior descending artery (LAD) involving the distal left main stem (LMS) (panel A). Abciximab was administered and a 3.5 mm Taxus stent (Boston Scientific, USA) was deployed, bridging the circumflex ostium. Flow was now compromised in the circumflex and a second stent (2.5 mm Taxus) was deployed at the circumflex ostium in a “T” configuration. Further dilatations were performed to both stents and a good final angiographic result was obtained (panel B).

Against medical advice the patient stopped clopidogrel at 10 days. Thirty days postangioplasty he presented to the emergency room at a referring hospital with acute chest pain. ECG showed anterior ST depression and lateral ST elevation. The patient was thrombolysed with tenecteplase and transferred for urgent coronary angiography. The LAD/LMS stent was widely patent, however, the circumflex stent contained thrombus (panel C) with TIMI 3 flow in the circumflex. As he was pain-free and stable a decision was made to attempt medical treatment. Tiroliban was administered for 48 hours. Angiography at 48 hours showed the thrombus in the circumflex had resolved (panel D). His ECG returned to normal and he suffered no further chest pain.

Stent thrombosis is believed to have occurred because of premature discontinuation of clopidogrel and was successfully managed medically with a combination of thrombolysis and glycoprotein IIb/IIIa inhibition. At four months follow up the patient was free of angina.

S E Bowater
S N Doshi
N P Buller
sagar.doshi@msnyuhealth.org

www.heartnl.com
Right ventricular functional recovery after acute myocardial infarction: relation with left ventricular function and interventricular septum motion. GISSI-3 echo substudy


Heart 2005 91: 484-488
doi: 10.1136/hrt.2003.028050

Updated information and services can be found at:
http://heart.bmj.com/content/91/4/484

References
This article cites 24 articles, 8 of which you can access for free at:
http://heart.bmj.com/content/91/4/484#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Acute coronary syndromes (2742)
- Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/